Treatment Outcomes for Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureuswith Reduced Vancomycin Susceptibility
Top Cited Papers
Open Access
- 15 February 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (4), 521-528
- https://doi.org/10.1086/381202
Abstract
Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.Keywords
This publication has 17 references indexed in Scilit:
- Epidemiological and Microbiological Characterization of Infections Caused byStaphylococcus aureuswith Reduced Susceptibility to Vancomycin, United States, 1997–2001Clinical Infectious Diseases, 2003
- The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic modelJournal of Antimicrobial Chemotherapy, 2001
- Vancomycin-resistant Staphylococcus aureus : a new model of antibiotic resistanceThe Lancet Infectious Diseases, 2001
- Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureusEmerging Infectious Diseases, 2001
- Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to KnowClinical Infectious Diseases, 2001
- Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf areaJournal of Antimicrobial Chemotherapy, 1999
- Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycinThe Lancet, 1999
- Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinThe Lancet, 1997
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997
- Evolution of resistance in Staphylococcus aureus in Australian teaching hospitalsThe Medical Journal of Australia, 1996